Table 4.
Multivariate Analysis for OS
| Covariate | Hazard Ratio | 95% CI | P |
|---|---|---|---|
| Treatment arm | |||
| R-BEAM | 1.00 | .55 | |
| B-BEAM | 1.14 | 0.73 to 1.78 | |
| Disease status at transplantation | |||
| CR | 1.00 | < .001 | |
| Not in CR | 2.42 | 1.47 to 3.96 | |
| Age at transplantation, years | |||
| < 50 | 1.00 | .027 | |
| ≥ 50 | 1.93 | 1.08 to 3.47 | |
| Interval from diagnosis to transplantation, months | |||
| < 15 | 1.00 | .001 | |
| ≥ 15 | 0.47 | 0.30 to 0.75 | |
| Sex | |||
| Female | 1.00 | .045 | |
| Male | 1.65 | 1.01 to 2.70 | |
| AST or ALT, units/L | |||
| < 25 | 1.00 | .042 | |
| ≥ 25 | 0.62 | 0.39 to 0.98 |
Abbreviations: B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; CR, complete remission; OS, overall survival; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.